You are here: Industry Insights > boehringer

News List

Boehringer acquires AMAL Therapeutics for $366m pharmaceutical-technology
July 17, 2019
Boehringer Ingelheim has expanded its cancer immunology portfolio with the acquisition of Swiss biotechnology firm AMAL Therapeutics for up to €325m ($366m).
Boehringer, Yuhan Enter NASH Pact contractpharma
July 09, 2019
To develop dual agonist for the treatment of NASH and related liver diseases that combines GLP-1 and FGF21 activity in one molecule.
Boehringer partners with Yuhan for liver disease drug pharmaceutical-technology
July 03, 2019
Boehringer Ingelheim has partnered with South Korea-based Yuhan for the development of a first-in-class compound to treat nonalcoholic steatohepatitis (NASH) and other related liver disorders.
Boehringer, Uni of Dundee extend anti-cancer alliance pharmatimes
June 19, 2019
Boehringer Ingelheim and the University of Dundee have highlighted the success of the PROTAC drug discovery program, and thus extended their ongoing anti-cancer alliance.
Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors drugs
June 19, 2019
Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors.
Boehringer expands PROTAC drugs partnership with Dundee University pharmaceutical-technology
June 13, 2019
Boehringer Ingelheim has extended a collaboration with the University of Dundee in Scotland for the development of proteolysis targeting chimera (PROTAC) based drugs to treat cancer.
ADA: Lilly, Boehringer's DPP-4 drug Tradjenta ties generic rival in heart safety study fiercepharma
June 12, 2019
Boehringer Ingelheim and Eli Lilly have already shown that Tradjenta doesn’t hurt patients’ hearts. But the pair is back with even more supporting evidence that they hope will bolster the drug's profile in a competitive field.
Patent litigation for adalimumab resolved in the US europeanpharmaceuticalreview
May 29, 2019
AbbVie has announced that it has resolved its US HUMIRA (adalimumab) litigation with Boehringer Ingelheim.
AbbVie and Boehringer settle Humira biosimilar patent dispute in US pharmaceutical-technology
May 16, 2019
AbbVie and Boehringer Ingelheim have settled a patent dispute in the US over Cyltezo (adalimumab-adbm), a biosimilar of Humira (adalimumab).
Boehringer buckles in AbbVie patent fight, saving Humira from biosims until 2023 fiercepharma
May 15, 2019
Boehringer Ingelheim fought hard against AbbVie’s so-called “patent thicket” surrounding the world’s bestselling med, Humira. But in the end, the German company ended up settling, just like its fellow biosimilar makers.

Previous page 1 2 3 4 5 6 Next page